Andrés Poveda, MD, Fundación Instituto Valenciano de Oncologia, Valencia, Spain, who was not involved in the Cediranib in Recurrent Cervical Cancer (CIRCCa) trial, said that the study provides supportive evidence that adding an antiangiogenic drug is beneficial in recurrent cervical cancer. Dr. Poveda moderated the European Society for Medical Oncology (ESMO) session where these data were presented.
“Bevacizumab [Avastin] was recently approved by the [U.S. Food and Drug Administration] for cervical cancer, and that changed clinical practice…. The impact on [progression-free survival] is important, and other trial objectives were reached, such as response rate,” Dr. Poveda said in an ESMO statement.
The hope is that a phase III trial of cediranib will be favorable and that this will be another new treatment for cervical cancer, he said. ■
Disclosure: Dr. Poveda reported no potential conflicts of interest.
Cediranib (a potent tyrosine kinase inhibitor of vascular endothelial growth factor receptor (VEGFR)-1, -2, and -3) produced a modest improvement in progression-free survival and a robust improvement in response rates compared with placebo when added to chemotherapy in patients with recurrent...